Rescuing the function of mutant p53

Nature Reviews Cancer

Volumn 1, Issue 1, 2001, Pages 68-76

  Bullock, Alex N ^a   Fersht, Alan R ^b  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

DNA; IMATINIB; PIPERAZINE DERIVATIVE; PROTEIN P53; PYRIMIDINE DERIVATIVE;

ANIMAL; CHEMISTRY; HUMAN; METABOLISM; MUTATION; PHYSIOLOGY; PROTEIN FOLDING; REVIEW;

ANIMALS; DNA; HUMANS; MUTATION; PIPERAZINES; PROTEIN FOLDING; PYRIMIDINES; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0035496607     PISSN: 1474175X     EISSN: None     Source Type: Journal    
DOI: 10.1038/35094077     Document Type: Article

References (15)

1. Hanahan, D. & Weinberg, R. A. The hallmarks of cancer. Cell 100, 57-70 (2000).
2. Finette, B. A., Homans, A. C. & Albertini, R. J. Emergence of genetic instability in children treated for leukemia. Science 288, 514-517 (2000).
3. Komarov, P. G. et al. A chemical inhibitor of p53 that protects mice from the side effects of cancer therapy. Science 285, 1733-1737 (1999). Traditional cancer therapies are invasive. DNA damage can occur in healthy cells and induce p53-dependent apoptosis. This paper describes an inhibitor of p53 that protects against these effects.
4. Sheer, C. J. The Pezcoller lecture: cancer cell cycles revisited. Cancer Res. 60, 3689-3695 (2000).
5. Hupp, T. R., Lane, D. P. & Ball, K. L. Strategies for manipulating the p53 pathway in the treatment of human cancer. Biochem. J. 352, 1-17 (2000). A recent review highlighting the progress of new approaches to cancer therapy based on restoring the p53 tumour-suppressor pathway.
6. Foster, B. A. et al. Pharmacological rescue of mutant p53 conformation and function. Science 286, 2507-2510 (1999). Reports the first screen for prototype pharmacological small molecules that stabilize the native structure of wild-type p53 conformation.
7. Lane, D. P. & Crawford, L. V. T antigen is bound to a host protein in SV40-transformed cells. Nature 278, 261-263 (1979).
8. Linzer, D. I. & Levine, A. J. Characterization of a 54K daltor cellular SV40 tumor antigen present in SV40-transformed cells and uninfected embryonal carcinoma cells. Cell 17, 43-52 (1979).
9. Lane, D. P. & Benchimol, S. p53: oncogene or antioncogene? Genes Dev. 4, 1-8 (1990).
10. Scheffner, M. et al. The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53. Cell 63, 1129-1136 (1990).
11. Kubbutat, M. H. Jones, S. N. & Vousden, K. H. Regulatior of p53 stability by Mdm2. Nature 387, 299-303 (1997).
12. Haupt, Y. et al. Mdm2 promotes the rapid degradation of p53. Nature 387, 296-299 (1997).
13. Jones, S. N. et al. Rescue of embryonic lethality in Mdm2-deficient mice by absence of p53. Nature 378, 206-208 (1995).
14. Montes de Oca Luna, R., Wagner, D. S. and Lozano, G. Rescue of early embryonic lethality in Mdm2-deficient mice by deletion of p53. Nature 378, 203-206 (1995).
15. de Rozieres, S. et al. The loss of Mdm2 induces p53-mediated apoptosis. Oncogene 19, 1691-1697 (2000).